Today’s Annual General Meeting of Lonza Group Ltd led by the Chairman of the Board of Directors, Rolf Soiron, was attended by 260 shareholders. They represented 37.1 % of the sharecapital.
The Shareholders carried all motions proposed by the Board of Directors.
A dividend of CHF 1.75 per share will be paid out on 16 April 2009.
Dame Julia Higgins, Gerhard Mayr, Rolf Soiron, Sir Richard Sykes, Patrick Aebischer and Peter Wilden were all elected for a further term in office of one year. As an additional member Frits van Dijk was newly elected to the Board of Directors. Peter Kalantzis will leave the board after having reached the maximum incumbency of nine years.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotech-nology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.94 billion. Further information can be found at www.lonza.com.
For further information:
Head Corporate Communications
Tel +41 61 316 8566
Fax +41 61 316 9566
Tel +41 61 316 8798
Fax +41 61 316 9798
Tel +41 61 316 8835
Fax +41 61 316 9835